Luminex Corporation

Former QuidelOrtho CEO Douglas Bryant Joins Board of Directors of Vital Biosciences

Retrieved on: 
Tuesday, April 9, 2024
Software, Research, General Health, Hardware, Data Management, Technology, Medical Devices, Health Technology, Clinical Trials, Science, FDA, Health, Other Science, San Diego Business Journal, Abbott Laboratories, EVP, QuidelOrtho, COVID-19, Patient, Luminex Corporation, Banda della Magliana, Acquisition, Labcorp, Vasu, Gen-Probe, Ortho Clinical Diagnostics, Blood, Management

Vital Biosciences today announced that Mr. Douglas Bryant has joined the company’s Board of Directors.

Key Points: 
  • Vital Biosciences today announced that Mr. Douglas Bryant has joined the company’s Board of Directors.
  • Vital Biosciences announced its work on a revolutionary new product, the VitalOne.
  • “Doug grew QuidelOrtho into a global leader in diagnostics, and a category defining company in point-of-care,” according to Vasu Nadella, CEO of Vital Biosciences.
  • He led the company during the acquisition of Ortho Clinical Diagnostics and subsequent renaming to QuidelOrtho in May 2022.

Aspira Women’s Health Expands Senior Leadership Team with the Addition of Sandra Milligan, M.D., J.D. as President

Retrieved on: 
Monday, March 18, 2024
Georgetown University Law Center, Ovarian cancer, Development, Acceleration, California State University, Luminex Corporation, Information technology, Standard of care, Senior, Respiratory disease, University, Gynaecology, Woman, Doctor of Philosophy, Research and development, Endometriosis, Drug development, Dana–Farber Cancer Institute, Therapy, Amgen, DIA, Human resources, Medical device

AUSTIN, Texas, March 18, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it has expanded its senior management team with the addition of Sandra Milligan, M.D., J.D. as President effective April 1, 2024. Dr. Milligan will report to Nicole Sandford, who will remain CEO. The Company has also promoted Dr. Todd Pappas, Vice President of Research & Development, to lead the Company’s product development team reporting directly to Dr. Milligan, following the departure of Dr. Jody Berry.

Key Points: 
  • The Company has also promoted Dr. Todd Pappas, Vice President of Research & Development, to lead the Company’s product development team reporting directly to Dr. Milligan, following the departure of Dr. Jody Berry.
  • She has demonstrated success in supporting pipeline and product development in both oncology and non-oncology disease areas, with recent emphasis in women’s health.
  • Dr. Milligan is a known and respected leader in women’s health who drives cross-functional strategies to achieve corporate success.
  • As President, Dr. Milligan will be a key member of the executive leadership team with direct responsibility for the Research and Development, Operations, Information Technology, and Human Resources functions.

Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook

Retrieved on: 
Wednesday, February 28, 2024
Luminex Corporation, Acquisition, Total, Research, Investment, Share repurchase, Marketing, Growth, Organic, Flow cytometry, Cryptocurrency

FREMONT, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • FREMONT, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2023.
  • Gross profit margin was 57% in the fourth quarter of 2023 compared to 61% in the fourth quarter of 2022.
  • Research and development expenses were $10.9 million for the fourth quarter of 2023 compared to $9.7 million for the fourth quarter of 2022.
  • Sales and marketing expenses were $11.6 million for the fourth quarter of 2023 compared to $9.0 million for the fourth quarter of 2022.

3D Systems Announces Organization Changes and New Executive Leadership Appointments

Retrieved on: 
Wednesday, December 13, 2023
Business transformation, Partnership, Luminex, Economics, Certified Management Accountant, CFO, American Public University System, Luminex Corporation, Marketing, Pfeiffer University, Regenerative medicine, Harriss, MBA, Certified Public Accountant, Interim management, University, Moses Austin, Interim, Growth, ROCK, 3D Systems, Senior, Management

ROCK HILL, S.C., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Today, 3D Systems (NYSE:DDD) announced two additions to its executive leadership team.

Key Points: 
  • ROCK HILL, S.C., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Today, 3D Systems (NYSE:DDD) announced two additions to its executive leadership team.
  • Mr. Creech joins 3D Systems with more than 25 years of experience in financial leadership and business transformation.
  • Mr. Currie will be joining 3D Systems with 30 years of experience in executive leadership with a focus on building emerging businesses.
  • “I’m pleased to welcome Jeffrey and Harriss to 3D Systems in these very important roles,” said Dr. Jeffrey Graves, president & CEO, 3D Systems.

Global Rapid Influenza Diagnostic Tests Market to Surpass $2.20 Billion by 2030 - CoherentMI

Retrieved on: 
Wednesday, December 6, 2023
QuidelOrtho, Pharynx, Thermo Fisher Scientific, Abbott Laboratories, Prevalence, DiaSorin, BD (company), Collection, Patient, Urinary tract infection, PerkinElmer, CE, Diagnosis, End user, Growth, Telehealth, Luminex Corporation, Vaccine

Two key trends can be observed in the global rapid influenza diagnostic tests market.

Key Points: 
  • Two key trends can be observed in the global rapid influenza diagnostic tests market.
  • Increasing demand for rapid influenza diagnostic tests: The global rapid influenza diagnostic tests market is anticipated to witness significant growth during the forecast period of 2023-2030.
  • Read complete market research report, " Global Rapid Influenza Diagnostic Tests Market Size And Share Analysis - Growth Trends And Forecasts (2023 - 2030) ", Published by CoherentMI.
  • In conclusion, the global rapid influenza diagnostic tests market is expected to witness significant growth due to the increasing demand for quick and accurate diagnosis of influenza.

Global Rapid Influenza Diagnostic Tests Market to Surpass $2.20 Billion by 2030 - CoherentMI

Retrieved on: 
Wednesday, December 6, 2023
QuidelOrtho, Pharynx, Thermo Fisher Scientific, Abbott Laboratories, Prevalence, DiaSorin, BD (company), Collection, Patient, Urinary tract infection, PerkinElmer, CE, Diagnosis, End user, Growth, Telehealth, Luminex Corporation, Vaccine

Two key trends can be observed in the global rapid influenza diagnostic tests market.

Key Points: 
  • Two key trends can be observed in the global rapid influenza diagnostic tests market.
  • Increasing demand for rapid influenza diagnostic tests: The global rapid influenza diagnostic tests market is anticipated to witness significant growth during the forecast period of 2023-2030.
  • Read complete market research report, " Global Rapid Influenza Diagnostic Tests Market Size And Share Analysis - Growth Trends And Forecasts (2023 - 2030) ", Published by CoherentMI.
  • In conclusion, the global rapid influenza diagnostic tests market is expected to witness significant growth due to the increasing demand for quick and accurate diagnosis of influenza.

Cytek Biosciences Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023
Research, Security (finance), Luminex Corporation, EBITDA, Acquisition, Organic, Environment, Growth, Marketing, Total, Investment, Video game, Cryptocurrency, Luminex

FREMONT, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • FREMONT, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2023.
  • Gross profit margin was 57% in the third quarter of 2023 compared to 66% in the third quarter of 2022.
  • Research and development expenses were $11.2 million for the third quarter of 2023 compared to $8.7 million for the third quarter of 2022.
  • Cytek will host a conference call to discuss the third quarter 2023 financial results on Tuesday, November 7, 2023, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Pattern Bioscience Strengthens Leadership Team with Key Appointments

Retrieved on: 
Tuesday, October 17, 2023
Health Technology, Technology, Nanotechnology, Stem Cells, Pharmaceutical, Professional Services, General Health, Infectious Diseases, Science, Biotechnology, Software, Data Analytics, Other Science, Health, Research, Diagnosis, MBA, Infection, Veteran, University, Machine learning, Moses Austin, Single-cell analysis, Luminex Corporation, DiaSorin, Economics, Disruptive innovation, Organization, Medical laboratory, Quality control, AACC, American Airlines, BS, Patient, BA, Microbiology, Accounting, Pneumonia, McKesson Corporation, CFO, Treasury, Global health, Pharmaceutical industry, Vaccine, Operation, Symantec

“Tim and Travis join us at a transformative moment in our quest to set a new standard in infectious disease diagnostics,” said Nick Arab, co-founder and CEO of Pattern Bioscience.

Key Points: 
  • “Tim and Travis join us at a transformative moment in our quest to set a new standard in infectious disease diagnostics,” said Nick Arab, co-founder and CEO of Pattern Bioscience.
  • “We are proud to add two proven veterans to our team as the company expands from development to validation and commercialization.
  • Pattern Bioscience is pioneering the use of single-cell microbiology to rapidly diagnose drug-resistant bacterial infections and identify effective treatments.
  • “Pattern Bioscience is redefining the speed and performance of bacterial diagnostics to help better address the growing threat of antibiotic resistance,” said Mr. Skansi.

Cytek Biosciences Appoints Dr. Philippe Busque Senior Vice President of Global Sales & Services

Retrieved on: 
Monday, August 28, 2023
Senior, Doctor of Philosophy, Amni, Research, Organization, Acquisition, Platform, Johnson & Johnson, Luminex Corporation, Microbiology, Fine chemical, Guava, Immunology

FREMONT, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the appointment of Philippe Busque, Ph.D. as Senior Vice President of Global Sales & Services.

Key Points: 
  • FREMONT, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the appointment of Philippe Busque, Ph.D. as Senior Vice President of Global Sales & Services.
  • In this newly created position, Dr. Busque will lead an enhanced global sales organization encompassing all customer facing functions worldwide, including sales, service, and technical application support, building on the recently integrated sales team that combines the original Cytek sales force with the Amnis® and Guava® sales force.
  • “Philippe’s extensive global sales and marketing experience as an executive at several life science companies, including Johnson & Johnson, Sony Biotechnology, and BD Biosciences, makes him an outstanding choice to lead our sales organization.
  • In parallel with these enhancements, Cytek’s Chief Commercial Officer, Todd Garland, is leaving Cytek for another opportunity.

Flow Cytometry Market worth $7.0 billion | MarketsandMarkets

Retrieved on: 
Wednesday, August 9, 2023
BioLegend, PlayStation Portable system software, Disease, Drug development, Drug discovery, Cancer research, Sartorius AG, Personalized medicine, Functional analysis, Research, Medicine, Agilent Technologies, Cell, Automation, Miniaturization, Disulfiram-like drug, Danaher Corporation, Transplant, Neuroscience, Acquisition, Laboratory, Machine learning, Microbiology, Flow cytometry, Apoptosis, Cell cycle, Hematology, Miltenyi Biotec, Luminex Corporation, SPS, Robotics, AI, B cell, Sony, Behavior, Sysmex Corporation, Computer data storage, Mobile phone, Pharmaceutical industry, Medical imaging

In June 2023, BD launched The BD FACSDuet Premium Sample Preparation System to automate sample preparation in clinical flow cytometry diagnostics.

Key Points: 
  • In June 2023, BD launched The BD FACSDuet Premium Sample Preparation System to automate sample preparation in clinical flow cytometry diagnostics.
  • In May 2023, Sysmex launched Clinical Flow Cytometry System Flow Cytometer XF-1600, Sample Preparation System PS-10, antibody reagents, and other related products in Japan.
  • Personalized Medicine: Flow cytometry contributes to personalized medicine by enabling tailored treatments based on individual patient profiles and disease characteristics.
  • These pointers highlight the multifaceted advantages of flow cytometry, making it an indispensable tool in scientific research, clinical diagnostics, and healthcare innovation.